抗体受託開発・製造機関の市場規模、シェア、動向分析レポート：製品別、供給源別、治療領域別、最終用途別、地域別、セグメント別予測、2023年～2030年

抗体CDMO（抗体受託開発・製造機関）市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の抗体CDMO市場は2023年から2030年にかけて14.0%のCAGRで拡大し、2030年には584億米ドルに達すると予測されています。

新規抗体治療薬の発見に関する研究開発活動の発展、がん患者の増加、開発・製造受託機関（CDMO）とバイオ製薬企業間の協力関係の高まりが、抗体CDMO市場の成長を促進する主な要因となっています。

抗体は薬物療法であり、特にがん治療に用いられます。これらの抗体は体内の健康な細胞に影響を与えず、薬剤の治療指数を向上させました。これらは、がん治療における抗体の需要が高い2つの主な理由です。これらの要因が、臨床研究における抗体薬物複合体（ADC）などの抗体タイプの開発を支えています。

がん治療における抗体の効率の高さから、バイオ医薬品企業は抗体関連の研究を行うために多額の資金援助を受けています。例えば、2022年10月、Mablink Bioscience社は、がん治療用の抗体ADCパイプラインを構築するため、シリーズA資金調達から3,100万米ドルを調達しました。同様に、2021年7月、ProfoundBioは、抗体ADCパイプラインの開発を加速するために投資家から5,500万米ドルを受け取っています。したがって、がん治療に関連する新規治療薬を開発するためのバイオ医薬品企業による取り組みが増加していることは、市場の成長を支える主な要因の1つです。

COVID-19の大流行は市場に大きな影響を与えました。しかし、いくつかの企業は、パンデミックの影響を緩和し、それによって売上収益の回復を目指すために、パートナーシップ、合併、買収などの組織内戦略的イニシアチブを採用しました。さらに、ウクライナとロシア間の地政学的戦争は抗体CDMO市場にマイナスの影響を与えています。これは米国など特定の国に大きな影響を与えており、そのため世界市場全体の収益は2022年中に緩やかに落ち込んでいます。

抗体CDMO市場レポートハイライト

• モノクローナル抗体セグメントは、2022年に67.6%の最大シェアを占めました。このセグメントは、抗がんベースのモノクローナル抗体治療薬に対する需要の高まりによって牽引され、抗体治療薬全体の大部分を構成しています。
• ソース別では、哺乳類セグメントが2022年に58.5%の最大シェアを占めました。このセグメントのシェアが高いのは、哺乳類抗体治療薬全体でアウトソーシングの割合が増加していることが主因です。そのため、CDMOは自社生産よりも比較的低コストで製造サービスを提供しており、市場での大きなシェアを支えています。
• 免疫介在性疾患分野は、予測期間中に最も速いCAGR 14.6%で成長すると予測されています。これは、免疫介在性疾患の治療における新規抗体の発見を目的とした臨床試験の割合が増加しているためです。
• バイオ医薬品企業は、2023年から2030年にかけて最も速いCAGR 14.3%で成長すると予想されます。これは、新規抗体治療薬の生産に注力するバイオ医薬品企業の増加によるもので、予測期間中の有利な成長を支えています。
• アジア太平洋地域は、予測期間中に14.2%という最も高いCAGRで成長すると予測されています。高い成長の主因は、インドや中国などのアジア諸国であり、生産コストが欧米諸国よりも比較的低いため、この地域全体でより多くの顧客層を惹きつけ、この地域の成長を支えています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 抗体CDMO市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因分析
• 抗体CDMO市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19感染症の影響分析
  • 抗体調査のための臨床試験量分析、（2022）
  • 規制状況：

第4章 抗体CDMO市場：製品推定・動向分析

• 抗体CDMO市場、製品別：セグメントダッシュボード
• 抗体CDMO市場、製品別：変動分析

第5章 抗体CDMO市場：供給源の推定・動向分析

• 抗体CDMO市場、供給源別：セグメントダッシュボード
• 抗体CDMO市場、供給源別：変動分析

第6章 抗体CDMO市場：治療領域の推定・動向分析

• 抗体CDMO市場、治療領域別：セグメントダッシュボード
• 抗体CDMO市場、治療領域別：変動分析

第7章 抗体CDMO市場：最終用途の推定・動向分析

• 抗体CDMO市場、最終用途別：セグメントダッシュボード
• 抗体CDMO市場、最終用途別：変動分析

第8章 抗体CDMO市場：地域推定・動向分析

• 地域市場シェア分析、2022年および2030年
• 地域市場ダッシュボード
• 世界の地域市場のスナップショット
• 北米
  • 市場推計・予測、2018～2030年
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋地域
  • 日本
  • インド
  • 中国
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 市場参入企業の分類
  • イノベーター
  • マーケットリーダー
  • 新興企業
  • 企業の市場シェア分析、2022年
• 企業プロファイル
  • Lonza
  • Catalent, Inc
  • Samsung Biologics
  • WuXi Biologics
  • AGC Biologics
  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Charles River Laboratories
  • FUJIFILM Holdings Corporation
  • mAbxience

List of Tables

• Table 1 List of secondary sources
• Table 2 List of Abbreviations
• Table 3 North America Antibody CDMO market, by region, 2018 - 2030 (USD Million)
• Table 4 North America Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 5 North America Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 6 North America Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 7 North America Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 8 U.S. Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 9 U.S. Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 10 U.S. Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 11 U.S. Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 12 Canada Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 13 Canada Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 14 Canada Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 15 Canada Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 16 Europe Antibody CDMO market, by region, 2018 - 2030 (USD Million)
• Table 17 Europe Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 18 Europe Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 19 Europe Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 20 Europe Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 21 UK Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 22 UK Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 23 UK Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 24 UK Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 25 Germany Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 26 Germany Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 27 Germany Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 28 Germany Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 29 France Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 30 France Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 31 France Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 32 France Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 33 Italy Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 34 Italy Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 35 Italy Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 36 Italy Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 37 Spain Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 38 Spain Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 39 Spain Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 40 Spain Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 41 Denmark Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 42 Denmark Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 43 Denmark Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 44 Denmark Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 45 Sweden Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 46 Sweden Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 47 Sweden Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 48 Sweden Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 49 Norway Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 50 Norway Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 51 Norway Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 52 Norway Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 53 Asia Pacific Antibody CDMO market, by region, 2018 - 2030 (USD Million)
• Table 54 Asia Pacific Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 55 Asia Pacific Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 58 China Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 59 China Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 60 China Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 61 China Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 62 Japan Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 63 Japan Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 64 Japan Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 65 Japan Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 66 India Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 67 India Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 68 India Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 69 India Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 70 Australia Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 71 Australia Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 72 Australia Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 73 Australia Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 74 South Korea Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 75 South Korea Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 76 South Korea Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 77 South Korea Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 78 Thailand Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 79 Thailand Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 80 Thailand Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 81 Thailand Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 82 Latin America Antibody CDMO market, by region, 2018 - 2030 (USD Million)
• Table 83 Latin America Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 84 Latin America Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 85 Latin America Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 86 Latin America Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 87 Brazil Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 88 Brazil Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 89 Brazil Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 90 Brazil Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 91 Mexico Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 92 Mexico Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 93 Mexico Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 94 Mexico Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 95 Argentina Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 96 Argentina Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 97 Argentina Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 98 Argentina Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 99 Middle East and Africa Antibody CDMO market, by region, 2018 - 2030 (USD Million)
• Table 100 Middle East and Africa Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 101 Middle East and Africa Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 102 Middle East and Africa Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 103 Middle East & Africa Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 104 South Africa Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 105 South Africa Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 106 South Africa Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 107 South Africa Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 111 Saudi Arabia Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 112 UAE Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 113 UAE Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 114 UAE Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 115 UAE Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
• Table 116 Kuwait Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
• Table 117 Kuwait Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
• Table 118 Kuwait Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 119 Kuwait Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Market research approaches
• Fig. 4 QFD modelling for market share assessment
• Fig. 5 Market formulation & validation
• Fig. 6 Commodity flow analysis
• Fig. 7 Primary research pattern
• Fig. 8 Primary interviews in North America
• Fig. 9 Primary interviews in Europe
• Fig. 10 Primary interviews in Asia Pacific
• Fig. 11 Primary interviews in Latin America
• Fig. 12 Primary interviews in MEA
• Fig. 13 Market Snapshot
• Fig. 14 Segment Snapshot
• Fig. 15 Competitive Landscape Snapshot
• Fig. 16 Antibody CDMO market segmentation
• Fig. 17 Parent market outlook (2022)
• Fig. 18 Related/ancillary market outlook (2022)
• Fig. 19 Market driver relevance analysis (Current & future impact)
• Fig. 20 Market restraint relevance analysis (Current & future impact)
• Fig. 21 Porter's five forces analysis
• Fig. 22 SWOT analysis, by a factor (political & legal, economic and technological)
• Fig. 23 Antibody CDMO Market Product outlook: Segment dashboard
• Fig. 24 Antibody CDMO :Product movement analysis
• Fig. 25 Monoclonal Antibodies market, 2018 - 2030 (USD Million)
• Fig. 26 Polyclonal Antibodies market, 2018 - 2030 (USD Million)
• Fig. 27 Others Antibodies market, 2018 - 2030 (USD Million)
• Fig. 28 Antibody CDMO Market Source outlook: Segment dashboard
• Fig. 29 Antibody CDMO : Source type movement analysis
• Fig. 30 Mammalian market, 2018 - 2030 (USD Million)
• Fig. 31 Microbial market, 2018 - 2030 (USD Million)
• Fig. 32 Antibody CDMO market Therapeutic Area outlook: Segment dashboard
• Fig. 33 Antibody CDMO market: Therapeutic Area movement analysis
• Fig. 34 Oncology market, 2018 - 2030 (USD Million)
• Fig. 35 Neurology market, 2018 - 2030 (USD Million)
• Fig. 36 Cardiology market, 2018 - 2030 (USD Million)
• Fig. 37 Infectious Diseases market, 2018 - 2030 (USD Million)
• Fig. 38 Immune-mediated Disorders market, 2018 - 2030 (USD Million)
• Fig. 39 Others market, 2018 - 2030 (USD Million)
• Fig. 40 Regional marketplace: Segment dashboard
• Fig. 41 Regional outlook, 2022 & 2030
• Fig. 42 North America market, 2018 - 2030 (USD Million)
• Fig. 43 U.S. market, 2018 - 2030 (USD Million)
• Fig. 44 Canada market, 2018 - 2030 (USD Million)
• Fig. 45 Europe market, 2018 - 2030 (USD Million)
• Fig. 46 Germany market, 2018 - 2030 (USD Million)
• Fig. 47 UK market, 2018 - 2030 (USD Million)
• Fig. 48 France market, 2018 - 2030 (USD Million)
• Fig. 49 Italy market, 2018 - 2030 (USD Million)
• Fig. 50 Spain market, 2018 - 2030 (USD Million)
• Fig. 51 Denmark market, 2018 - 2030(USD Million)
• Fig. 52 Sweden market, 2018 - 2030 (USD Million)
• Fig. 53 Norway market, 2018 - 2030 (USD Million)
• Fig. 54 Asia Pacific market, 2018 - 2030 (USD Million)
• Fig. 55 China market, 2018 - 2030 (USD Million)
• Fig. 56 Japan market, 2018 - 2030 (USD Million)
• Fig. 57 India market, 2018 - 2030 (USD Million)
• Fig. 58 Australia market, 2018 - 2030 (USD Million)
• Fig. 59 Thailand market, 2018 - 2030 (USD Million)
• Fig. 60 South Korea market, 2018 - 2030 (USD Million)
• Fig. 61 Latin America market, 2018 - 2030 (USD Million)
• Fig. 62 Brazil market, 2018 - 2030 (USD Million)
• Fig. 63 Mexico market, 2018 - 2030 (USD Million)
• Fig. 64 Argentina market, 2018 - 2030 (USD Million)
• Fig. 65 Middle East & Africa market, 2018 - 2030 (USD Million)
• Fig. 66 South Africa market, 2018 - 2030 (USD Million)
• Fig. 67 Saudi Arabia market, 2018 - 2030 (USD Million)
• Fig. 68 UAE market, 2018 - 2030 (USD Million)
• Fig. 69 Kuwait market, 2018 - 2030 (USD Million)

Antibody CDMO Market Growth & Trends:

The global antibody CDMO market is expected to reach USD 58.40 billion by 2030, expanding at a CAGR of 14.0% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Increasing R&D activities pertaining to the discovery of novel antibody therapeutics, growing prevalence of cancer cases and rising collaborations amongst contract development & manufacturing organizations (CDMO) and biopharmaceutical companies are the key factors driving the growth of antibody CDMO market.

Antibodies are drug therapies, especially used in cancer treatment. These antibodies do not affect healthy cells in the body and improve the therapeutic index of the drug; these are two key reasons for the high demand for antibodies in the treatment of cancer. These factors have supported the development of antibody types such as Antibody-drug conjugates (ADCs) in clinical research.

Owing to the efficiency of antibodies in cancer treatment, biopharmaceutical companies are receiving a significant amount of funding for conducting antibody-related research. For instance, in October 2022, Mablink Bioscience raised USD 31 million from Series A funding to build its antibody ADC pipeline for cancer treatment. Similarly, in July 2021, ProfoundBio received USD 55 million from investors to accelerate the development of the antibody ADC pipeline. Hence, increasing efforts via biopharmaceutical companies to develop novel therapeutics pertaining to the treatment of cancer is one of the major factors supporting the market growth.

The COVID-19 pandemic had a considerable impact on the market. However, several players adopted in-organic strategic initiatives such as partnerships, mergers, and acquisitions to mitigate the impact of the pandemic and thereby witness a rebound in their sales revenue. Moreover, the geopolitical war between Ukraine and Russia has negatively impacted the antibody CDMO market, as clinical trials outsourced across the war-infected countries have been halted until further notice. This has greatly impacted certain countries, such as the U.S., due to which the overall global market has witnessed a moderate dip in its revenue during 2022.

Antibody CDMO Market Report Highlights:

• Monoclonal antibodies segment accounted for the largest share of 67.6% in 2022.The segment is driven by growing demand for anti-cancer-based monoclonal antibody treatment therapeutics, constituting a vast portion of the overall antibody therapeutics
• Based on the source, the mammalian segment accounted for the largest share of 58.5% in 2022. High shares of the segment are majorly due to increasing rates of outsourcing witnessed across mammalian antibody therapeutics, as the cost of production of such antibodies is significantly high. Hence, CDMOs offer these manufacturing services at a comparatively lower cost than in-house production rates, thus supporting its large segment share in the market
• The immune-mediated disorders segment is anticipated to register the fastest CAGR of 14.6% during the forecast period. This is due to the growing rate of clinical trials targeted at discovering novel antibodies in the treatment of immune-mediated disorders
• Biopharmaceutical companies are anticipated to register the fastest CAGR of 14.3% from 2023 to 2030, owing increasing number of biopharmaceutical companies focusing on producing novel antibody therapeutics, thus supporting its lucrative growth during the forecast period
• Asia Pacific is anticipated to witness the highest CAGR of 14.2% during the forecast time frame. High growth is majorly due to Asian countries such as India and China, where the cost of production is comparatively lower than in Western economies, thus attracting a larger customer base across the region and thereby supporting the region's growth

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Definitions
  • 1.1.2. Product
  • 1.1.3. Source
  • 1.1.4. Therapeutic Area
  • 1.1.5. End Use
• 1.2. Regional Scope
• 1.3. Estimates And Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective-1
  • 1.4.2. Objective-2
  • 1.4.3. Objective-3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information Or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. Parent Market Analysis
• 1.10. List Of Secondary Sources
• 1.11. List Of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Antibody CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Rate of Clinical Research to Boost Demand for Antibody CDMO Services
    • 3.2.1.2. Rising Incidence of Cancer
    • 3.2.1.3. High Cost of Manufacturing Antibodies and Challenges Associated with Manufacturing Contributing to Demand For Outsourcing Services
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Quality Issues While Outsourcing
    • 3.2.2.2. Limited Outsourcing Opted by Big Biopharma Companies
• 3.3. Antibody CDMO Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat Of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis
  • 3.3.4. Clinical Trial Volume Analysis for Antibody Research, (2022)
  • 3.3.5. Regulatory Landscape:
    • 3.3.5.1. U.S.
    • 3.3.5.2. Europe
    • 3.3.5.3. Asia Pacific
    • 3.3.5.4. Rest of the World

Chapter 4. Antibody CDMO Market: Product Estimates & Trend Analysis

• 4.1. Antibody CDMO Market, By Product: Segment Dashboard
• 4.2. Antibody CDMO Market, By Product: Movement Analysis
• 4.3. Antibody CDMO Market Estimates & Forecasts, By Product, 2018 - 2030
  • 4.3.1. Monoclonal Antibodies
    • 4.3.1.1. Monoclonal Antibodies Antibody CDMO Market, 2018 to 2030, (USD Million)
  • 4.3.2. Polyclonal Antibodies
    • 4.3.2.1. Polyclonal Antibodies Antibody CDMO Market, 2018 to 2030, (USD Million)
  • 4.3.3. Others
    • 4.3.3.1. Others Antibody CDMO Market, 2018 to 2030, (USD Million)

Chapter 5. Antibody CDMO Market: Source Estimates & Trend Analysis

• 5.1. Antibody CDMO Market, By Source: Segment Dashboard
• 5.2. Antibody CDMO Market, By Source: Movement Analysis
• 5.3. Antibody CDMO Market Estimates & Forecasts, By Source, 2018 - 2030
  • 5.3.1. Mammalian
    • 5.3.1.1. Mammalian Antibody CDMO Market, 2018 to 2030 (USD Million)
  • 5.3.2. Microbial
    • 5.3.2.1. Microbial Antibody CDMO Market, 2018 to 2030, (USD Million)

Chapter 6. Antibody CDMO Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Antibody CDMO Market, By Therapeutic Area: Segment Dashboard
• 6.2. Antibody CDMO Market, By Therapeutic Area: Movement Analysis
• 6.3. Antibody CDMO Market Estimates & Forecasts, By Therapeutic Area, 2018 - 2030
  • 6.3.1. Oncology
    • 6.3.1.1. Oncology Antibody CDMO Market 2018 to 2030 (USD Million)
  • 6.3.2. Neurology
    • 6.3.2.1. Neurology Antibody CDMO Market 2018 to 2030 (USD Million)
  • 6.3.3. Cardiology
    • 6.3.3.1. Cardiology Antibody CDMO Market 2018 to 2030 (USD Million)
  • 6.3.4. Infectious Diseases
    • 6.3.4.1. Infectious Diseases Antibody CDMO Market 2018 to 2030 (USD Million)
  • 6.3.5. Immune-mediated Disorders
    • 6.3.5.1. Immune-mediated Disorders Antibody CDMO Market 2018 to 2030 (USD Million)
  • 6.3.6. Others
    • 6.3.6.1. Others Antibody CDMO Market 2018 to 2030 (USD Million)

Chapter 7. Antibody CDMO Market: End Use Estimates & Trend Analysis

• 7.1. Antibody CDMO Market, By End Use: Segment Dashboard
• 7.2. Antibody CDMO Market, By End Use: Movement Analysis
• 7.3. Antibody CDMO Market Estimates & Forecasts, By End Use, 2018 - 2030
  • 7.3.1. Biopharmaceutical Companies
    • 7.3.1.1. Biopharmaceutical Companies Antibody CDMO Market 2018 to 2030 (USD Million)
  • 7.3.2. Research Laboratories
    • 7.3.2.1. Research Laboratories Antibody CDMO Market 2018 to 2030 (USD Million)
  • 7.3.3. Others
    • 7.3.3.1. Others Antibody CDMO Market 2018 to 2030 (USD Million)

Chapter 8. Antibody CDMO Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2022 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. North America
  • 8.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
• 8.5. Europe
  • 8.5.1. UK
    • 8.5.1.1. Key Country Dynamics
    • 8.5.1.2. Competitive Scenario
    • 8.5.1.3. Regulatory Framework
    • 8.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
  • 8.5.2. Germany
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
  • 8.5.3. France
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
  • 8.5.4. Italy
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
  • 8.5.5. Spain
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
  • 8.5.6. Denmark
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
  • 8.5.7. Sweden
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
  • 8.5.8. Norway
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key Country Dynamics
    • 8.6.1.2. Competitive Scenario
    • 8.6.1.3. Regulatory Framework
    • 8.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
  • 8.6.2. India
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
  • 8.6.4. South Korea
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
  • 8.6.6. Thailand
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
• 8.7. Latin America
  • 8.7.1. Brazil
    • 8.7.1.1. Key Country Dynamics
    • 8.7.1.2. Competitive Scenario
    • 8.7.1.3. Regulatory Framework
    • 8.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
  • 8.7.2. Mexico
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
• 8.8. MEA
  • 8.8.1. South Africa
    • 8.8.1.1. Key Country Dynamics
    • 8.8.1.2. Competitive Scenario
    • 8.8.1.3. Regulatory Framework
    • 8.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
  • 8.8.2. Saudi Arabia
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
  • 8.8.3. UAE
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
  • 8.8.4. Kuwait
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
  • 9.1.1. Innovators
  • 9.1.2. Market Leaders
  • 9.1.3. Emerging Players
  • 9.1.4. Company Market Share Analysis, 2022
• 9.2. Company Profiles
  • 9.2.1. Lonza
    • 9.2.1.1. Company Overview
    • 9.2.1.2. Financial Performance
    • 9.2.1.3. Service Benchmarking
    • 9.2.1.4. Strategic Initiatives
  • 9.2.2. Catalent, Inc
    • 9.2.2.1. Company Overview
    • 9.2.2.2. Financial Performance
    • 9.2.2.3. Service Benchmarking
    • 9.2.2.4. Strategic Initiatives
  • 9.2.3. Samsung Biologics
    • 9.2.3.1. Company Overview
    • 9.2.3.2. Financial Performance
    • 9.2.3.3. Service Benchmarking
    • 9.2.3.4. Strategic Initiatives
  • 9.2.4. WuXi Biologics
    • 9.2.4.1. Company Overview
    • 9.2.4.2. Financial Performance
    • 9.2.4.3. Service Benchmarking
    • 9.2.4.4. Strategic Initiatives
  • 9.2.5. AGC Biologics
    • 9.2.5.1. Company Overview
    • 9.2.5.2. Financial Performance
    • 9.2.5.3. Service Benchmarking
    • 9.2.5.4. Strategic Initiatives
  • 9.2.6. AbbVie Inc.
    • 9.2.6.1. Company Overview
    • 9.2.6.2. Financial Performance
    • 9.2.6.3. Service Benchmarking
    • 9.2.6.4. Strategic Initiatives
  • 9.2.7. Boehringer Ingelheim International GmbH
    • 9.2.7.1. Company Overview
    • 9.2.7.2. Financial Performance
    • 9.2.7.3. Service Benchmarking
    • 9.2.7.4. Strategic Initiatives
  • 9.2.8. Charles River Laboratories
    • 9.2.8.1. Company Overview
    • 9.2.8.2. Financial Performance
    • 9.2.8.3. Service Benchmarking
    • 9.2.8.4. Strategic Initiatives
  • 9.2.9. FUJIFILM Holdings Corporation
    • 9.2.9.1. Company Overview
    • 9.2.9.2. Financial Performance
    • 9.2.9.3. Service Benchmarking
    • 9.2.9.4. Strategic Initiatives
  • 9.2.10. mAbxience
    • 9.2.10.1. Company Overview
    • 9.2.10.2. Financial Performance
    • 9.2.10.3. Service Benchmarking
    • 9.2.10.4. Strategic Initiatives